Journal
MICROBIOLOGY AND IMMUNOLOGY
Volume 60, Issue 4, Pages 253-260Publisher
WILEY-BLACKWELL
DOI: 10.1111/1348-0421.12372
Keywords
-lapachone; IMR-32; JCI; JC polyomavirus; topotecan
Categories
Funding
- Research Committee of Prion Disease and Slow Virus Infection
- Ministry of Health, Labor and Welfare of Japan
- High-Tech Center of Kanazawa Medical University [H2011-10]
- JSPS [26461286]
- Grants-in-Aid for Scientific Research [25430119, 26461286] Funding Source: KAKEN
Ask authors/readers for more resources
JC polyomavirus (JCPyV) causes progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the central nervous system, in immunocompromised patients. Because no drugs have been approved for treating PML, many antiviral agents are currently being investigated for this purpose. The inhibitory effects of the topoisomerase I inhibitors topotecan and -lapachone were assessed by investigating viral replication, propagation and viral protein 1 (VP1) production in cultured cells. JCPyV replication was assayed using the human neuroblastoma cell line IMR-32 transfected with the JCPyV plasmid and RT- PCR combined with Dpn I treatment. Dpn I digests the input plasmid DNA containing methylated adenosine, but not newly replicated JCPyV DNA, in IMR-32 cells. It was found that JCPyV replicates less in IMR-32 cells treated with topotecan or -lapachone than in untreated cells. Moreover, drug treatment of JCI cells, which are IMR-32 cells persistently infected with JCPyV, led to a reduction in the amount of JCPyV DNA and population of VP1-positive cells. These results demonstrate that topotecan and -lapachone affects JCPyV propagation in human neuroblastoma cell lines, suggesting that topotecan and -lapachone could potentially be used to treat PML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available